Cargando…

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trabjerg, Natacha Dencker, Rask, Christina, Jensen, Lars Henrik, Hansen, Torben Frøstrup
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637362/ https://www.ncbi.nlm.nih.gov/pubmed/31360509 http://dx.doi.org/10.1002/ccr3.2262

Ejemplares similares

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Investigating whether shared video-based consultations with patients, oncologists, and GPs can benefit patient-centred cancer care: a qualitative study
por: Trabjerg, Theis Bitz, et al.
Publicado: (2020)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer
por: Ma, Jian, et al.
Publicado: (2017)

Re‐exposure to immunotherapy in metastatic colon cancer: A case report
por: Hamre, Tonje Riise, et al.
Publicado: (2021)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
por: Ikeda, Taro, et al.
Publicado: (2021)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
por: Reddy, Tejaswini Parlapalle, et al.
Publicado: (2020)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
por: Grierson, Patrick, et al.
Publicado: (2017)

Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
por: Jensen, Lars Henrik, et al.
Publicado: (2023)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis
por: Karani, Amanda, et al.
Publicado: (2020)

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
por: Kunimatsu, Yusuke, et al.
Publicado: (2023)

Glioblastoma with brainstem leptomeningeal pseudoprogression following radiation therapy
por: Kinger, Nikhar, et al.
Publicado: (2019)

Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression?
por: Trunin, Yury, et al.
Publicado: (2017)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts
por: Hansen, Torben Frøstrup, et al.
Publicado: (2018)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
por: Carausu, Marcela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5fkjp6n3gvefrt8apjvqeb1pm2